Revelation Biosciences (REVB) Stock Price, News & Analysis

Company Overview

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Key Stats

• Today's Range: $3.00 to $3.30
• 50-Day Range: $2.60 to $3.69
• 52-Week Range: $2.36 to $60.80
• Volume: 17,399 shs
• Average Volume: 127,461 shs
• Market Capitalization: $2.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REVB Stock Analysis - Frequently Asked Questions

How have REVB shares performed this year?

Revelation Biosciences' stock was trading at $7.3760 at the beginning of 2025. Since then, REVB shares have decreased by 58.6% and is now trading at $3.05.
View the best growth stocks for 2025 here.

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (NASDAQ:REVB) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($2.11) EPS for the quarter, topping analysts' consensus estimates of ($6.88) by $4.77.

When did Revelation Biosciences' stock split?

Revelation Biosciences's stock reverse split on Tuesday, January 28th 2025. The 1-16 reverse split was announced on Friday, January 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Revelation Biosciences?

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Revelation Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revelation Biosciences investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Wayfair (W), Abbott Laboratories (ABT), JPMorgan Chase & Co. (JPM) and Bank of America (BAC).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:REVB
• CIK: 1810560
• Web: www.revbiosciences.com
• Phone: 650-800-3717
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($102.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-120,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -193.51%
• Return on Assets: -84.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.64
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $402.10 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 905,000
• Free Float: 268,000
• Market Cap: $2.76 million
• Optionable: Not Optionable
• Beta: 0.19